Evaxion A/S – Sponsored ADR (NASDAQ:EVAX – Get Free Report) fell 8% during mid-day trading on Tuesday. The company traded as low as $2.72 and last traded at $2.76. 133,749 shares were traded during mid-day trading, an increase of 234% from the average session volume of 40,029 shares. The stock had previously closed at $3.00.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Evaxion A/S in a research note on Tuesday, October 6th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $11.00.
Check Out Our Latest Analysis on Evaxion A/S
Evaxion A/S Price Performance
The business has a fifty day moving average of $3.15 and a two-hundred day moving average of $3.47. The company has a current ratio of 5.06, a quick ratio of 5.06 and a debt-to-equity ratio of 0.69. The company has a market cap of $25.26 million, a price-to-earnings ratio of -2.31 and a beta of 0.50.
Institutional Investors Weigh In On Evaxion A/S
A number of hedge funds have recently modified their holdings of EVAX. Rathbones Group PLC purchased a new position in shares of Evaxion A/S during the 1st quarter worth $170,000. Renaissance Technologies LLC purchased a new stake in shares of Evaxion A/S in the 1st quarter valued at $146,000. Finally, Annis Gardner Whiting Capital Advisors LLC purchased a new position in Evaxion A/S during the 1st quarter valued at about $112,000. Hedge funds and other institutional investors own 11.04% of the company’s stock.
Evaxion A/S Company Profile
Evaxion A/S is a Denmark-based biotechnology company developing artificial intelligence-driven immunotherapies. The company’s technology is designed to identify disease-specific targets, known as antigens, and support the development of personalized treatments that stimulate a patient’s immune system to recognize and attack diseased cells or pathogens.
Evaxion’s research programs have focused primarily on personalized cancer immunotherapies, including EVX-01, as well as vaccines and immunotherapies for infectious diseases caused by bacteria and viruses.
Further Reading
- Five stocks we like better than Evaxion A/S
- ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing
- Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans
- AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle
- Beyond the GPU: Credo Paves the Next AI Data Superhighway
Receive News & Ratings for Evaxion A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion A/S and related companies with MarketBeat.com's FREE daily email newsletter.
